AEON Biopharma, Inc. (AEON): Nasdaq/NYSE listing notice — AEON Biopharma receives NYSE American delisting notice over stockholder deficit of $32.1M

AEON Biopharma, Inc.

Received notice on Feb 3, 2025 for non-compliance with Section 1003(a)(i) requiring $2M+ stockholders' equity.
Reported stockholders' deficit of $32.1M as of Sept 30, 2024 and losses in two of the three most recent fiscal years.
Must submit a compliance plan by March 5, 2025; has until Aug 3, 2026 to regain compliance.
If plan not accepted or fails, delisting proceedings will commence; shares will trade with ".BC" designation.
No immediate impact on listing or business operations; company intends to submit a plan.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 1003(a)(i)

Exact text from the filing

February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 1003(a)(i)

Exact text from the filing

recent fiscal years (the “Minimum Requirement”), as defined in Section 1003(a)(i) of the Company Guide. Pursuant to the Notice, the Company reported a stockholders’ deficit of $32.1 million at September 30, 2024 and has had losses in the two most recent fiscal years ended December 31, 2023 based on the Company’s Annual Report on Form 10-K/A filed with the U.S.

View on SEC.gov

Browse all listing & compliance notices →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.